Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Scientific reports - 21 Aug 2015

Pillinger Genevra, Abdul-Aziz Amina, Zaitseva Lyubov, Lawes Matthew, MacEwan David J, Bowles Kristian M, Rushworth Stuart A

Abstract excerpt

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently our group and others have shown that pharmacologic inhibition and genetic knockdown of Bruton's tyrosine kinase (BTK)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blast Crisis

Share to Daunorubicin

Share to fms-Like Tyrosine Kinase 3

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 26292723
DOI: 10.1038/srep12949
PMCID: PMC4544001

Genes

FLT3
BTK
SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.PMID 26292723Read ↗

FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferationSemantic proximity Read ↗

Targeting FLT3 for the treatment of leukemia.Semantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.Semantic proximity Read ↗

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Semantic proximity Read ↗

The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.Semantic proximity Read ↗

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.Semantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Flt3 receptor tyrosine kinase as a drug target in leukemia.Semantic proximity Read ↗

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.Semantic proximity Read ↗

Role of FLT3 in leukemia.Semantic proximity Read ↗

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.